SB 365 is a bill relating to a Board of Pharmacy rule on inspections. Based on the caption, the measure appears to address how pharmacy inspections are conducted under the Board of Pharmacy’s regulatory authority, likely by amending or authorizing a rule governing inspection procedures, standards, or timing. Because the bill text was not available in the provided materials, the precise changes to the inspection framework cannot be identified from the record supplied here.
The bill’s practical effect would be to alter state administrative law governing pharmacy oversight, potentially affecting licensed pharmacies, pharmacists, inspectors, and the Board of Pharmacy itself. Depending on the rule change, it could modify compliance obligations, inspection frequency, enforcement procedures, or the scope of the Board’s authority to inspect pharmacy premises and records. Any statutory impact would likely be limited to the pharmacy regulation chapter and related administrative provisions.
Impact
SB 365 would affect state regulation of pharmacies by changing the Board of Pharmacy’s inspection rule, which could in turn alter inspection standards, compliance expectations, and enforcement practices for licensed pharmacies and related facilities. The bill appears to operate through administrative rulemaking rather than creating a new substantive licensing scheme, so its legal impact would likely be on the implementation and administration of existing pharmacy oversight statutes.
Sentiment
There is no committee transcript or recorded vote information provided, so the overall sentiment cannot be measured directly from debate or roll call history. The bill’s referral to the Judiciary committee suggests it was still in the early stages of legislative review. On the available record, there is no evidence of either support or opposition, only that the measure was moving through the normal committee process.
Contention
No specific points of contention are documented in the materials provided. If concerns arise, they would likely center on the balance between public safety and regulatory burden: pharmacies may question the scope, frequency, or intrusiveness of inspections, while regulators and public-health advocates may favor stronger inspection authority to ensure compliance and patient safety. Without the bill text or discussion transcript, however, those issues remain speculative.
Relating to authorizing the Board of Pharmacy to promulgate a legislative rule relating to the application of waiver of initial licensing fees for certain individuals